EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serological methods for the detection of antibodies against monkeypox virus applicable for laboratories with different biosafety levels

Marica Grossegesse, Daniel Stern, Natalie Hofmann, Rebecca Surtees, Claudia Kohl, Janine Michel, Andreas Nitsche

Journal of Medical Virology · 2023-12 · 95 (12)

DOI: 10.1002/jmv.29261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 06.12.2023. Verfasst von Marica Grossegesse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Robert Koch Institute, Centre for Biological Threats and Special Pathogens: Highly Pathogenic Viruses (ZBS 1), Berlin, Germany. Hauptthemen laut MEDLINE: Monkeypox virus, Containment of Biohazards. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The monkeypox virus (MPXV) outbreak in 2022 has renewed interest in the detection of antibodies against orthopox viruses (OPXV) and MPXV, as serological methods can aid diagnostics and are key to epidemiological studies. Here three complementary serological methods are described with different strengths to aid the development and evaluation of in‐house assays: An immunofluorescence assay (IFA) for specific detection of IgG and IgM, an enzyme‐linked immunosorbent assay for higher sample throughput to aid epidemiological studies and a neutralization test to detect virus neutralizing antibodies. As implementation of MPXV‐specific diagnostics is often hampered by the requirement for a dedicated biosafety level 3 laboratory (BSL‐3), the focus of this study is on biosafety aspects to facilitate safe testing also under BSL‐2 conditions. To this aim, it was analyzed whether OPXV, which can be handled under BSL‐2 conditions, could be used as less virulent alternatives to MPXV. Furthermore, an inactivation method was established to remove up to five log‐steps of infectious virus particles from viraemic sera without compromising antibody detection. The results show that immunological cross‐reactivity between OPXV provides an opportunity for the interchangeable usage of different OPXV species in serological assays, enabling MPXV serology outside of BSL‐3 facilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monkeypox virusContainment of BiohazardsHumansLaboratoriesAntibodies, ViralNeutralization TestsMpox, Monkeypox

Stichwörter der Autor:innen

antibody detectionmonkeypox virusorthopox virusserologyvirus inactivation

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Robert Koch Institute, Centre for Biological Threats and Special Pathogens: Highly Pathogenic Viruses (ZBS 1), Berlin, Germany.
  • Robert Koch Institute, Centre for Biological Threats and Special Pathogens: Biological Toxins (ZBS 3), Berlin, Germany.

Zitieren

APA

Grossegesse, M., Stern, D., Hofmann, N., Surtees, R., Kohl, C., Michel, J., & Nitsche, A. (2023). Serological methods for the detection of antibodies against monkeypox virus applicable for laboratories with different biosafety levels. Journal of Medical Virology, 95(12). https://doi.org/10.1002/jmv.29261

Vancouver

Grossegesse M, Stern D, Hofmann N, Surtees R, Kohl C, Michel J, et al. Serological methods for the detection of antibodies against monkeypox virus applicable for laboratories with different biosafety levels. Journal of Medical Virology. 2023;95(12). doi:10.1002/jmv.29261

BibTeX
@article{Grossegesse2023,
  author = {Grossegesse, Marica and Stern, Daniel and Hofmann, Natalie and Surtees, Rebecca and Kohl, Claudia and Michel, Janine and Nitsche, Andreas},
  title = {Serological methods for the detection of antibodies against monkeypox virus applicable for laboratories with different biosafety levels},
  journal = {Journal of Medical Virology},
  year = {2023},
  volume = {95},
  number = {12},
  doi = {10.1002/jmv.29261}
}
Kostenlos starten →